Advancements in nanotheranostics for glioma therapy
Naunyn-Schmiedeberg's Archives of Pharmacology · 2025
DOI: 10.1007/s00210-024-03559-w ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Liza Sahoo und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Biotechnology, Centurion University of Technology and Management, Jatni, Bhubaneswar, 752050, Odisha, India. Hauptthemen laut MEDLINE: Glioma, Brain Neoplasms, Theranostic Nanomedicine, Antineoplastic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 270 Literaturangaben.
Abstract (Originalsprache)
Gliomas are brain tumors mainly derived from glial cells that are difficult to treat and cause high mortality. Radiation, chemotherapy, and surgical excision are the conventional treatments for gliomas. Patients who have surgery or have undergone chemotherapy for glioma treatment have poor prognosis with tumor recurrence. In particular, for glioblastoma, the 5-year average survival rate is 4-7%, and the median survival is 12-18 months. A number of issues hinder effective treatment such as, poor surgical resection, tumor heterogeneity, insufficient drug penetration across the blood-brain barrier, multidrug resistance, and difficulties with drug specificity. Nanotheranostic-mediated drug delivery is becoming a well-researched consideration, and an efficient non-invasive method for delivering chemotherapeutic drugs to the target area. Theranostic nanomedicines, which incorporate therapeutic drugs and imaging agents for personalized therapies, can be used for preventing overdose of non-responders. Through the identification of massive and complicated information from next-generation sequencing, machine learning enables for precise prediction of therapeutic outcomes and post-treatment management for patients with cancer. This article gives a thorough overview of nanocarrier-mediated drug delivery with a brief introduction to drug delivery challenges. In addition, this assessment offers a current summary of preclinical and clinical research on nanomedicines for gliomas. In the future, nanotheranostics will provide personalized treatment for gliomas and other treatable cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biotechnology, Centurion University of Technology and Management, Jatni, Bhubaneswar, 752050, Odisha, India.
- , Toronto, Canada. dfe.anthony@gmail.com.
- School of Biotechnology, Centurion University of Technology and Management, Jatni, Bhubaneswar, 752050, Odisha, India. fahimadilnawaz@gmail.com.
ORCID-Profile: Donald Fernandes, Fahima Dilnawaz
Zitieren
APA
Sahoo, L., Paikray, S. K., Tripathy, N. S., Fernandes, D., & Dilnawaz, F. (2025). Advancements in nanotheranostics for glioma therapy. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-024-03559-w
Vancouver
Sahoo L, Paikray SK, Tripathy NS, Fernandes D, Dilnawaz F. Advancements in nanotheranostics for glioma therapy. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-024-03559-w
BibTeX
@article{Sahoo2025,
author = {Sahoo, Liza and Paikray, Safal Kumar and Tripathy, Nigam Sekhar and Fernandes, Donald and Dilnawaz, Fahima},
title = {Advancements in nanotheranostics for glioma therapy},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2025},
doi = {10.1007/s00210-024-03559-w}
}
EUVIMED